June 3, 2017 12:14 PM EDT

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

John Carroll

Editor & Founder

CHICAGO — Typically, when you update your early-stage data with a couple of new complete responses to report, the biopharma world finds other things to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

John Carroll

Editor & Founder

Sign up to read this article for free.

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Agenus launches biologics manufacturing business to generate cash

In­cyte keeps the AS­CO spot­light fo­cused on its close­ly-watched IDO1 drug epaca­do­stat

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Agenus launches biologics manufacturing business to generate cash